Managing type 2 diabetes mellitus by coupling immunity modulatory and antidiabetic properties

Alteration in glycemic levels is known to modulate immune function. Regulatory T cell’s energy generation can be increased by mitochondria. Unwanted inflammation is brought on when mitochondrial danger-associated molecules are produced without an infection being present. Immuno-metabolism is the term for metabolic processes that support the cellular differentiation of immune components and/or disease development caused by inflammation. In type 2 diabetes mellitus, myeloid cells experience metabolic stress and causes beta-cell failure. The proportion and functioning of regulatory T cells fall due to decreased number of Treg cells. Insulin resistance and other metabolic diseases are influenced by T-reg cell depletion. The persistent low-grade inflammatory syndrome accompanying diabetes results from this insufficient anti-inflammatory response. Interleukin-35 and Interleukin-10, two anti-inflammatory cytokines, are known to prevent acute and protracted endothelial cell activation caused by reactive oxygen species while protecting the trained immune system. Inflammation is a key indicator of diabetes since it significantly raises morbidity and death. Conventional treatments provide incomplete protection from diabetes as well as diabetic complications. Novel approaches that look beyond the solitaire control of hyperglycemia and treat inflammation in conjugation with hyperglycemia may prove to be a more attractive tactic to counter type 2 diabetes especially those involving synergism.